Due to the temporary closing of Genzyme’s Allston plant last summer, MBBP client Shire’s new Gaucher Disease treatment VPRIV was fast-tracked and approved by the FDA.
Shire is now reporting data from a Phase 3 study which showed that when patients switched from Genzyme’s Cerezyme to Shire’s VPRIV, in the same dosage, several key health indicators remained the same.
For more information, please visit Shire.
